Several high-yielding dividend stocks recently raised their payouts again. With more dividend growth likely, this trio are great stocks to buy and hold for a steadily rising stream of passive income.

Worried about the next round of tariffs? Tech disruption from DeepSeek? The geopolitical landscape? Then these low-beta dividend stocks could be the answer.

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment. It could begin competing with generic versions in the U.S. market in 2028, but the gap it leaves won't be too difficult to fill. Eliquis is responsible for only about 10.3% of Pfizer's total revenue stream.